Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$9.69 -0.18 (-1.82%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$9.57 -0.12 (-1.19%)
As of 08/8/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Key Stats

Today's Range
$9.60
$10.03
50-Day Range
$8.40
$11.45
52-Week Range
$5.15
$16.73
Volume
579,893 shs
Average Volume
808,887 shs
Market Capitalization
$843.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.14
Consensus Rating
Buy

Company Overview

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

IMNM MarketRank™: 

Immunome scored higher than 34% of companies evaluated by MarketBeat, and ranked 752nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunome has only been the subject of 2 research reports in the past 90 days.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunome's valuation and earnings.
  • Percentage of Shares Shorted

    18.49% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently increased by 12.88%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.49% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently increased by 12.88%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Immunome has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Immunome this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,900.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.69% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

IMNM Stock News Headlines

Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $23.14
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Immunome (IMNM) Q2 Revenue Surges 382%
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $10.62 at the beginning of the year. Since then, IMNM shares have decreased by 8.8% and is now trading at $9.69.

Immunome, Inc. (NASDAQ:IMNM) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.02. The company earned $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative trailing twelve-month return on equity of 76.10% and a negative net margin of 1,687.08%.

Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

Top institutional investors of Immunome include Geode Capital Management LLC (2.14%), TD Asset Management Inc (0.70%), Nan Fung Trinity HK Ltd. (0.63%) and Candriam S.C.A. (0.37%). Insiders that own company stock include Clay B Siegall, Max Rosett, Bruce Turner, Jean Jacques Bienaime, Philip Tsai, Jack Higgins and Robert Lechleider.
View institutional ownership trends
.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/06/2025
Today
8/10/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNM
CIK
1472012
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$20.00
Potential Upside/Downside
+138.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$292.96 million
Net Margins
-1,687.08%
Pretax Margin
-1,875.21%
Return on Equity
-78.93%
Return on Assets
-66.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.49
Quick Ratio
10.49

Sales & Book Value

Annual Sales
$12.59 million
Price / Sales
67.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.27 per share
Price / Book
4.27

Miscellaneous

Outstanding Shares
87,045,000
Free Float
79,559,000
Market Cap
$843.47 million
Optionable
Optionable
Beta
1.93

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 8/11/2025 by MarketBeat.com Staff
From Our Partners